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Abstract
Background: Preanalytical conditions determine the reliability and validity of bioassays. Therefore, the analytic
performances of biological tests need to be determined when preanalytical steps differ from those recommended
by the manufacturer. The objective of the study was to assess the analytic performance of the hc2 test for the
detection of high-risk HPV DNA from cells stored in the new Novaprep® HQ+ medium.
Methods: Repeatability, reproducibility, method comparison and stability (-20 °C, +4 °C, +20 °C and +40 °C up to
six months) were evaluated from HPV16 and HPV18 positive cell lines diluted in the Novaprep® HQ+ medium and
the reference Specimen Transport Medium (STM). A series of cervical samples with atypical squamous cells of
undetermined significance (ASC-US) cytology and stored in the Novaprep® HQ+ medium was also tested.
Results: Coefficients of variation for repeatability and reproducibility were less than 8 %. Method comparison
showed perfect agreement in hc2 results when the HPV-positive cells were diluted in HQ+ and reference media.
Stability experiments demonstrated that the storage conditions did not alter the hc2 test results. Furthermore,
clinical samples were adequately preserved for hc2 testing.
Conclusions: Overall, our data show that the new Novaprep HQ+ medium is suitable for high-risk HPV testing
by hc2.
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Background
According to Arbyn’s meta-analysis, the sensitivity of
both conventional and liquid-based cytology (LBC)
remains low (below 60 %) for the detection of high grade
squamous intraepithelial lesions (HSIL) of the cervix [1].
High-risk human papillomavirus (hrHPV) testing has
been proposed to overcome the limits of cervical cy-
tology for the triage of women with atypical squamous
cells of undetermined significance (ASC-US) cytology
[2]. Moreover, alone or in combination with cytology,
hrHPV testing allows screening of HSIL or cancers with
high sensitivity and negative predictive value [3–6]. In
this way, introducing HPV testing as a primary screening
test may improve the safety and cost-effectiveness of
cervical cancer screening [4, 7–10].
Among the most reliable HPV DNA tests, the hybrid
capture 2 test (hc2) is a nucleic acid hybridization assay
with signal amplification. This technique has been
validated by the manufacturer using the Specimen
Transport Medium (STM) (Qiagen, Hilden, Germany),
the ThinPrep Pap Test (Hologic, Marlborough, MA,
USA) and the BD SurePath™ liquid-based Pap test (BD,
Franklin Lakes, NJ, USA) to collect cervical cells. In
2010, we conducted a clinical study to assess the suit-
ability of the LBC Novaprep® Vial Test system (Novacyt,
Vélizy-Villacoublay, France) for hrHPV DNA detection
in cervical samples using the hc2 test. Very high agree-
ment for hrHPV DNA detection was found between two
consecutive cervical samples deposited in the Novaprep®
Vial Test and in the reference medium STM (Qiagen)
[11]. Since this study, the fixative composition of the
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Novaprep® system has been slightly modified and the
product is now called Novaprep® HQ+ Orange. The
objective of this study was to assess whether the modifi-
cations of the Novaprep LBC medium impact the per-
formance of the hc2 assay to detect hrHPV DNA. A
comprehensive evaluation of repeatability, reproduc-
ibility, method comparison and stability was conducted to
identify potential sources of variation and interference.
Methods
Cell lines
The human Ca Ski (HVP16, 400 to 600 copies per cell)
and SiHa (HVP16, 1 to 2 copies per cell) cell lines, the
HeLa (HPV18, 20 to 40 copies per cell) cell line and the
HPV negative C33-A cell line were obtained from ATCC
(Manassas, VA, USA) and routinely tested for the pres-
ence of HPV in our laboratory. Ca Ski and SiHa cells
were maintained at 37 °C (5 % CO2) in complete RPMI
or DMEM respectively (Lonza, Levallois-Perret, France)
supplemented with 10 % fetal bovine serum (FBS;
Lonza), 5x104 U/L penicillin/streptomycin (Lonza) and
2 mM L-glutamine (Lonza). HeLa and C33-A cells were
grown in complete EMEM (Lonza) supplemented with
10 % FBS, 5x104 U/L penicillin/streptomycin and
2 mM L-glutamine.
HPV positive and HPV negative cells were diluted at
indicated concentrations in the STM (Digene/Qiagen,
Courtaboeuf, France) as reference medium and in the
Novaprep® HQ+ Orange medium (Novacyt, Vélizy-
Villacoublay, France), an alcohol-based fixative primarily
dedicated to liquid-based cytology. Because pretreatment of
viscous samples with dithiothreitol (DTT), a mucolytic
agent, may be recommended to provide mucus-free single-
cell suspensions, Novacyt also provided the Novaprep®
HQ+ orange containing 0.03 % DTT. For conveni-
ence, the Novaprep® HQ+ medium without DTT will be
referred to as HQ+A and the Novaprep® HQ+ medium
with DTT will be referred to as HQ+ B.
Cervical samples
Three hundred and twenty two consecutive samples
collected at the endocervical-ectocervical junction
with a cytobrush, conserved in Novaprep® HQ+ Orange
medium and with an ASC-US diagnosis were routinely
tested for hrHPV with the Digene hc2 High-Risk HPV
DNA Test (Qiagen). All samples were stored in a biobank
approved by the local ethics committee (Comité de
Protection des Personnes Est II), and for which a declaration
of collection and storage of human samples for research use
has been lodged with the French Ministry of Higher
Education and Research (Ministère de l’Enseignement
Supérieur et de la Recherche) (declaration number
DC-2014-2086).
Repeatability and reproducibility
Repeatability of hc2 testing was assessed by calculating
the mean, the standard deviation (SD), and the coeffi-
cient of variation (CV) of relative light units/cutoff
(RLU/CO) from 14 replicates prepared extemporan-
eously with medium HQ +A and medium HQ + B. This
assessment was conducted using three concentration
levels of HPV16 + cells (corresponding to 1.25x105 and
1.25x106 SiHa cells and 6.25x104 Ca Ski cells per mL)
and HPV18 + cells (corresponding to 3.12x104, 6.25x104
and 6.25x105 HeLa cells per mL) expected to give clinic-
ally relevant RLU/CO values. Assessment of the repro-
ducibility of hc2 testing was conducted using three
different batches of HQ +A and HQ + B media (namely
HQ+ A1; HQ+ A2; HQ+ A3; HQ+ B1; HQ+ B2; HQ+
B3). Fourteen replicates of 1.25x105 SiHa cells/mL were
prepared extemporaneously with the different batches of
media. The mean, SD and CV of RLU/CO were calcu-
lated from 42 replicates for each media.
Method comparison
Method comparison was conducted using six HPV16
positive samples and 6 HPV negative samples prepared
extemporaneously with the reference medium STM and
with HQ + A and HQ + B media. HPV positive samples
consisted of 5x104 and 2.5x104 Ca Ski cells/mL and
2.5x106, 1.25x106, 6x105 and 3x105 SiHa cells/mL. The
HPV negative C33-A cells were used to obtain 2.5x106,
1.25x106 and 6x105, 3x105, 1.5x105 and 0 cells/mL. Each
sample was analyzed in duplicate. The sensitivity and
specificity of hrHPV detection were calculated for each
medium.
Stability
For stability, the effect of time and temperature of
storage was analyzed using freshly prepared SiHa cells
(1.7x105 cells/mL) stored in the three batches of HQ +A
and HQ + B media up to 6 months at 18 to 25 °C (hc2
analysis was performed at weeks 0, 2, 4, 6, 8, 10, 12, 16,
24 and 28) and at -15 to -30 °C (hc2 analysis at weeks 2,
4 and 28) and up to 3 months at 2 to 8 and 40 °C (hc2
analysis at weeks 2, 4, 6, 8, 10, 12 and 16).
Human papillomavirus DNA detection
High-Risk HPV DNA testing was performed with the
hc2 High-Risk HPV DNA Test® (Qiagen/Digene) accord-
ing to the manufacturer’s instructions. For the denatur-
ation step, the protocol dedicated to samples collected
in the PreservCyt solution was applied to cellular
samples (cell lines or cervical samples) collected in
Novaprep® HQ+ Orange media without and with DTT.
Briefly, 0.1 volume of sample conversion buffer (Qiagen)
was added to each tube containing 1 mL of HPV posi-
tive or HPV negative cells collected and stored in
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Novaprep®HQ+ orange. After vortexing, cells were cen-
trifuged at 2900 g for 15 min (±2 min) and supernatant
was carefully decanted. Then 300 μL (1 mL for the
method comparison) of Specimen Transport Medium/
Denaturing Reagent mixture (in a 2:1 ratio) was added
to cell pellets that were resuspended by vortexing. The
denaturation step was conducted for 15 min at 65 °C,
then specimens were vortexed and incubated at 65 °C
for another 30 min. A 75 μL aliquot of denatured sam-
ples was processed for hybridization as recommended by
the manufacturer. All experiments were conducted with
the same batch of hc2 High-Risk HPV DNA Test®.
Results
Means, SD and CV for repeatability and reproducibility
are presented in Tables 1 and 2 respectively. The CV for
repeatability varied from 2.4 to 7.6 % according to the
media tested and the genotype detected. As regards
reproducibility, the CV were in the same range as those
obtained for repeatability, namely 6 % for the three
batches of medium HQ+A and 8 % for the three batches
of medium HQ+B. As a whole, these CV were very satis-
factory and were lower than the CV proposed by the
manufacturer for their internal Quality Control (25 %).
For method comparison, the ability of the hc2 test to as-
sign the sample status without error was assessed from
HPV16 positive and HPV negative cells diluted in HQ+A
and HQ+ B media in comparison with cells diluted in the
STM reference medium. As shown in Table 3, all HPV16
positive samples gave a RLU/CO > 1 and all HPV negative
samples gave a RLU/CO < 1, regardless of the medium.
Accordingly, the sensitivity and specificity of the hc2 test
for hrHPV DNA detection from cells diluted in HQ+A
and HQ + B media were 100 %, as was the case for
cells diluted in STM. Furthermore, the non-parametric
Friedman test showed that the RLU/CO values given by
HPV positive samples did not differ according to the
medium used to collect cells.
hrHPV DNA stability was tested at four different tem-
peratures, two of which corresponded to worst-case con-
ditions (between -15 to -30 and +40 °C). As shown in
Table 4, the RLU/CO values given by the hc2 test were
very similar over the entire duration of the experiment,
irrespective of the medium, batch and storage tem-
perature. We observed slightly lower RLU/CO values for
cells collected in the medium with DTT and stored at
4 °C than for other conditions.
Among the 322 cytology samples from women with
atypical squamous cells of undetermined significance
(ASC-US), 204 were hrHPV positive and 118 were
hrHPV negative.
Discussion
Accreditation of medical laboratories according to ISO
15189 standards is becoming a requirement for medical
laboratories throughout Europe [12]. This implies that
laboratory procedures, which include the preanalytical
steps, must be validated and verified before applied for
clinical testing, in order to ensure reliable results. In-
deed, evaluations of biological tests, independently from
the manufacturers, are crucial to choose the most appro-
priate test [13].
Table 1 Repeatability analysis of HPV16 and HPV18 DNA by hc2
Mean RLU/CO SD CV%
HPV16 HQ+ A
Low 32 1.4 4.3
Medium 231 10.5 4.5
High 2780 69.9 2.5
HPV16 HQ+ B
Low 35 1.3 3.7
Medium 247 12.5 5.1
High 2953 69.6 2.4
HPV18 HQ+ A
Low 9 0.7 7.6
Medium 18 0.8 4.1
High 146 7.0 4.8
HPV18 HQ+ B
Low 11 0.5 4.6
Medium 21 1.1 5.5
High 158 8.4 5.3
RLU/CO relative light units/cutoff, SD standard deviation, CV coefficient of
variation, HQ+ A Novaprep® HQ+ medium without DTT, HQ + B Novaprep®
HQ+ medium with DTT
Table 2 Reproducibility analysis of HPV16 DNA by hc2 using 3 batches of medium A and B
Batches HQ+ A1 HQ+ A2 HQ+ A3 HQ+ B1 HQ+ B2 HQ+ B3
Mean (each series) 27 27 29 30 29 29
Mean all series 28 29
SD all series 1.7 2.4
CV% 6 8
Abbreviations as in Table 1
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According to the manufacturer, the hc2 test has CE In
Vitro Diagnostics (IVD) certification for cell samples
harvested in 3 media, namely STM (Qiagen), PreservCyt
(Hologic) and SurePath (BD). Some studies have re-
ported the potential use of cell samples processed with
different liquid-based cytology media for hrHPV testing
by hc2 [11, 14–17]. We report here that the performance
characteristics of the hc2 assay are appropriate for its
intended use with cells stored in the new Novaprep®
HQ+ medium with or without DTT. Thus, pretreatment
of cervical smears with a mucolytic agent (DTT up to
0.03 %) to obtain single-cell suspensions does not alter the
specimen for further hrHPV DNA testing by hc2. In the
same way, the adjunct of glacial acetic acid (GAA) in LBC
specimen to lyse red blood cells has been evaluated and
studies confirmed that GAA pretreatment had no signifi-
cant impact on analytical and clinical performance of
HPV tests [18–20].
To identify potential sources of variation and/or inter-
ference due only to fixatives, each series of experiments
(repeatability, reproducibility, method comparison and
stability) was conducted using unique batches of cells
and hc2 kits from the same batch number.
The coefficients of variation of the hc2 test ranged
from 2.4 to 7.6 % for repeatability and 6 to 8 % for re-
producibility. Such CVs are very satisfactory. Indeed,
they are lower than 25 %, the maximum CV value that
may be allowed within each series of samples to validate
the test in quality controls. Moreover, the CVs observed
here are lower than the value obtained with our own in-
ternal quality control, namely 18 %.
The method comparison made it possible to assess the
robustness of hrHPV DNA detection by hc2 with cell
samples prepared with Novaprep® HQ+ orange with or
without DTT, in comparison with cells samples prepared
with STM. Again, the results were more than adequate.
hrHPV detection was as efficient with cells diluted in
the two Novaprep® HQ+ orange media (A and B) as with
cells diluted in STM. Furthermore, no cell samples
stored in Novaprep® HQ+ orange medium and known to
be positive or negative for the target were misclassified
(false positive or false negative) after hrHPV DNA test-
ing with the hc2 test.
Ensuring the stability of cervical samples is mandatory,
since HPV testing may be delayed. Indeed, screening
algorithms recommend hrHPV DNA testing as a triage
test for women with cytological abnormalities. This is
the case in France, where reflex HPV is an option follow-
ing ASC-US cytology. Furthermore, in some situations,
Table 3 Method comparison
hc2
Pos Neg Total
STM pos 12 0 12
STM neg 0 12 12
total 12 12
HQ+ A pos 12 0 12
HQ+ A nega 0 11 11
total 12 11
HQ+ B pos 12 0 12




HQ+ A 100 100
HQ+ B 100 100
Pos positive, Neg negative
aOne missing sample due to error in distribution
Se sensitivity, Sp specificity
HQ+ A Novaprep® HQ+ medium without DTT, HQ + B Novaprep® HQ+ medium
with DTT
Table 4 Stability of samples diluted in media A and B
RLU/CO
18 °C to 25 °C 2 °C to 8 °C 40 °C -15 °C to -30 °C
Weeks A1 A2 A3 B1 B2 B3 A1 A2 A3 B1 B2 B3 A1 A2 A3 B1 B2 B3 A1 A2 A3 B1 B2 B3
0 41 42 36 37 37 39 - - - - - - - - - - - - - - - - - -
2 51 48 45 36 47 62 49 52 48 36 41 41 51 67 51 48 59 48 52 46 46 48 50 48
4 51 42 47 44 46 53 54 49 44 36 45 43 53 54 50 49 39 43 47 45 48 49 57 50
6 49 51 46 46 46 50 53 52 52 31 35 35 47 44 52 45 49 45 - - - - - -
8 51 54 50 41 50 43 48 55 40 35 38 32 54 49 55 40 46 52 - - - - - -
10 41 41 42 38 36 38 41 45 39 28 36 33 42 40 42 40 42 38 - - - - - -
12 45 42 43 35 40 47 49 40 46 29 33 29 50 47 47 37 43 42 - - - - - -
16 48 52 50 42 43 33 49 51 47 34 31 36 49 48 42 44 47 42 - - - - - -
24 34 33 33 33 29 31 - - - - - - - - - - - - - - - - - -
28 44 43 42 43 39 36 - - - - - - - - - - - 43 45 42 40 40 43
RLU/CO relative light units/cutoff
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samples must be shipped to a distant molecular biology
laboratory in charge of hrHPV testing. The stability ex-
periment conducted in this study demonstrates that both
HQ+A and HQ+ B media adequately preserve hrHPV
DNA and allow for its efficient detection with hc2 up to
6 months at room temperature (18-25 °C), and up to
3 months in refrigerated conditions (+4 °C). Moreover, ex-
cellent stability was demonstrated in the two “worst-case”
scenarios, namely samples stored betwen -15°C to -30°C
for 6 months and at +40 °C for 3 months. The Novaprep®
HQ+ orange media with or without DTT are particularly
well adapted for countries with a tropical or equatorial cli-
mate, where air-conditioning may not be systematically
available. In a practical point of view, the rate of hrHPV
detection from cervical samples with ASC-US cytology
stored in the Novaprep® HQ+ LBC medium was 63 %. This
rate, similar to that published with ASC-US samples stored
in SurePath media [21], indicates a good hrHPV DNA
preservation.
The robustness of the Novaprep HQ+ medium for
hrHPV DNA detection was also recently demonstrated
with the real-time PCR based Cobas® 4800 HPV test
[22]. Although the study by Khiri, as well as our own
results, suggest that it would be possible to use cells
collected in Novaprep® HQ+ orange medium for hrHPV
DNA detection by molecular testing, this does not by
any means exempt each individual laboratory from
the need to verify/validate the method according to
ISO15189 standards before using this medium in routine
practice. Furthermore, Hortlund et al. suggested that the
clinical sensitivity of HPV test should be annually assessed
to warrant high quality results [23].
Conclusion
This study provides evidence that the Novaprep® HQ+
orange medium does not alter viral DNA preservation
and does not render cell samples inadequate for hrHPV
DNA testing with hc2.
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